This Morning's Technical Outlook on Generic Drugs Stocks -- Versartis, Diplomat Pharmacy, Mallinckrodt, and Zoetis

Wednesday, January 17, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 17, 2018 /PRNewswire/ --

WallStEquities.com strives to bring the best free research to the investment

community.  Today we are offering reports on VSAR, DPLO, MNK, and ZTS which can be accessed for free by signing up to http://www.wallstequities.com/registration. For today, WallStEquities.com draws investors' attention to Versartis Inc. (NASDAQ:
VSAR), Diplomat Pharmacy Inc. (NYSE: DPLO), Mallinckrodt PLC (NYSE: MNK), and Zoetis Inc. (NYSE: ZTS). These companies operate in the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. All you have to do is sign up today for this free limited time offer by clicking the link below. http://www.wallstequities.com/registration

Versartis

On Tuesday, shares in Menlo Park, California headquartered Versartis Inc. recorded a trading volume of 337,144 shares. The stock ended the session 1.16% lower at $2.13. The Company's shares have gained 8.97% in the last month. The stock is trading 6.33% above its 50-day moving average. Moreover, shares of Versartis, which operates as an endocrine-focused biopharmaceutical company in the US, have a Relative Strength Index (RSI) of 52.94. Get the full research report on VSAR for free by clicking below at: http://www.wallstequities.com/registration/?symbol=VSAR

Diplomat Pharmacy

Flint, Michigan headquartered Diplomat Pharmacy Inc.'s stock closed the day 1.58% lower at $25.52. A total volume of 1.23 million shares was traded, which was above their three months average volume of 747,850 shares. The Company's shares have surged 25.96% in the past month, 25.65% in the previous three months, and 81.51% over the past year. The stock is trading 29.43% and 42.02% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 75.99. DPLO's complimentary research coverage is a few simple steps away at: http://www.wallstequities.com/registration/?symbol=DPLO

Mallinckrodt

Shares in Staines-Upon-Thames, the UK headquartered Mallinckrodt PLC recorded a trading volume of 2.14 million shares. The stock ended yesterday's trading session 1.57% lower at $23.13. The Company's shares are trading slightly above their 50-day moving average by 0.01%. Furthermore, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, EMEA region, and internationally, have an RSI of 53.02.

On January 09th, 2018, research firm Mizuho reiterated its 'Neutral' rating on the Company's stock with a decrease of the target price from $22 a share to $21 a share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on MNK at: http://www.wallstequities.com/registration/?symbol=MNK

Zoetis

Parsippany, New Jersey headquartered Zoetis Inc.'s stock finished Tuesday's session 0.20% higher at $75.54. A total volume of 2.59 million shares was traded, which was above their three months average volume of 2.31 million shares. The Company's shares have advanced 4.37% in the last month, 15.43% over the previous three months, and 40.57% over the past year. The stock is trading above its 50-day and 200-day moving averages by 5.77% and 18.37%, respectively. Additionally, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have an RSI of 70.67.

On January 04th, 2018, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'. Aspiring Member, please take a moment to register below for your free research report on ZTS at: http://www.wallstequities.com/registration/?symbol=ZTS

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 

 

Cision View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-generic-drugs-stocks----versartis-diplomat-pharmacy-mallinckrodt-and-zoetis-300583802.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store